- Published at
- by manilatimes.net
positive
positive
News for Nippon Shinyaku Co., Ltd. (4516N.MX)
- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
positivepositive- Published at
- by investing.com
mixedmixedREGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases By Investing.com
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases- Published at
- by gurufocus.com
positivepositiveCapricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy- -BLA submission triggers $10 million milestone payme- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveCapricor Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics ( CAPR), a biotechnology company developing transformative cell and exosome-based therapeut- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveCapricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Milestone represents a significant step forward in the development of deramiocel for the treatment of Duchenne muscular dystrophy in the European region SAN D- Published at
- by manilatimes.net
positivepositive- Published at
- by manilatimes.net
neutralneutral- Published at
- by investing.com
positivepositiveCapricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting By Investing.com
Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting- Published at
- by globenewswire.com
mixedmixed80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight
With over 80 key companies active in the RNA therapies space, the market is projected to grow due to advancements in mRNA, siRNA, and antisense...- Published at
- by marketscreener.com
mixedmixedNippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan -March 26, 2024 at 03:06 am EDT
NEWS RELEASE March 26, 2024 UCB Japan Obtained Additional Application of Fintepla® for the Treatment of Seizures...- Published at
- by globenewswire.com
mixedmixedAntihypertensive Drugs Market Projected to Expand at a CAGR of 3.0% from 2022 to 2030, Data by Contrive Datum Insights
Farmington, Jan. 16, 2023 (GLOBE NEWSWIRE) -- The Antihypertensive Drugs Market is estimated to reach a valuation of USD 30.2 Billion by 2022, growing at...UTHRRETAPFED.BAPFECL.SNPFE.SNPFE.MXPFE.DEPFENVSN.MXNVSEFNVSD.BANVSNPPNYNPNKFNOVN.SWN1VS34.SAMRKD.BAMRK.SNMRK.PAMRK.MXMRKLLY.MXLLY.DELLY.BALLYLILY34.SAKYKOFJNJGIS.DEGILDD.BAGILD.MXGILDDJNJ3.BADJNJ2.BA6MK.DE4516N.MX4516.T4151.T0Q1G.L0K9E.L009420.KS003850.KSZEG.DESKXJFBLPHAZNN.MXAZNCFAZN.LAZN6417.T0HMP.L0A4J.L001067.KS001065.KS001060.KS